Jiantao Fu
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Metabolic outcomes of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir/lamivudine in treatment-naïve people living with HIV: a 48-week retrospective study.
Journal: Expert review of anti-infective therapy
Published: May 04, 2026
A carbon-based single-atom Cu electrocatalyst for efficient conversion of CO2 to carbon products.
Journal: Chemical communications (Cambridge, England)
Published: September 15, 2025
24-month outcomes after switching to Dolutegravir/Lamivudine in people living with HIV and HBcAb positivity at the Beijing Ditan Hospital in China.
Journal: Annals of medicine
Published: February 24, 2025
Temporal trends and clinical outcomes of antiretroviral therapy initiation and regimens in treatment-naive people with HIV: A real-world study at a tertiary specialist hospital in Beijing, China.
Journal: Infectious diseases & immunity
Published: February 06, 2025
Over-activation and dysfunction of platelet-NK cell aggregates in HIV-infected individuals.
Journal: Journal of translational medicine
Published: February 03, 2025
Efficacy and safety of switching from lopinavir/ritonavir-based regimens to bictegravir/emtricitabine/tenofovir alafenamide in people living with HIV: A multicenter retrospective study.
Journal: Virologica Sinica
Published: January 15, 2025
IRF8 Drives Conventional Type 1 Dendritic Cell Differentiation and CD8+ T Cell Activation to Aggravate Abdominal Aortic Aneurysm Development.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: December 04, 2024
Inhibitory interferon regulatory factor 5 binding peptide suppresses abdominal aortic aneurysm expansion in vivo.
Journal: Journal of molecular and cellular cardiology
Published: July 28, 2024
Single-Cell RNA Sequencing Deconstructs the Distribution of Immune Cells Within Abdominal Aortic Aneurysms in Mice.
Journal: Arteriosclerosis, thrombosis, and vascular biology
Published: July 25, 2024
Reasons, Efficacy and Safety of Switching to Dolutegravir-Based Regimens Among Virologically Suppressed PLWH: A Retrospective Cohort Study of 96 Weeks.
Journal: Infection and drug resistance
Published: December 05, 2023
Last Updated: 09/26/2026